Metabasis Therapeutics Inc., of San Diego, began a Phase I trial of MB07811

Amylin Pharmaceuticals Inc., of San Diego, said it is expanding its clinical program in obesity with five additional studies to assess the safety and efficacy of multiple neurohormones used in combination to treat obesity

Orexigen Therapeutics Inc., of San Diego, said Excalia, a combination of two centrally acting medications intended to provide and sustain clinically important weight loss, demonstrated significant weight loss in a six-month, double-blind, Phase IIa study...Somaxon Pharmaceuticals Inc., of San Diego, reported positive results from the first of three Phase III trials to evaluate the effect of Silenor (doxepin HCl) on sleep onset in transient insomnia

Hollis-Eden Pharmaceuticals Inc., of San Diego, reported data at the Infectious Disease Society of America meeting in Toronto showing that patients treated with Neumune (HE2100) had elevated neutrophil and platelet levels from baseline through at least 28 days

Ceregene Inc., of San Diego, said the gene therapy CERE-120 for Parkinson's disease was well tolerated and appeared to reduce symptoms by approximately 40 percent (p<0.001), as measured by the Unified Parkinson's Disease Rating Scale motor "off" score, in an open-label Phase I study in 12 patients with advanced disease...Halozyme Therapeutics Inc., of San Diego, completed enrollment in a clinical trial of subcutaneous morphine with Hylenex, a liquid injectable indicated as an adjuvant to increase

Kalypsys Inc., of San Diego, initiated a Phase Ia study of KD3010, for metabolic diseases and expects to complete it in October

Orexigen Therapeutics Inc., of San Diego, said top-line Phase III results for the company's lead obesity compound, Contrave, demonstrated significant advantages in weight loss in a 24-week trial, which will continue unblinded for an additional 24 weeks

Acadia Pharmaceuticals Inc., of San Diego, provided an update on the timing of its Phase II adjunctive therapy trial with ACP-103 in patients with schizophrenia, saying enrollment is ahead of schedule, which should enable the company to report top-line results for the complete 400-patient clinical trial during the first quarter of 2007, ahead of earlier expectations...Adventrx Pharmaceuticals Inc., of San Diego, completed patient enrollment in a 300-patient Phase IIb trial designed to compare the

Those data were presented at the 92nd annual meeting of the American Academy of Periodontology in San Diego

Amylin Pharmaceuticals Inc., of San Diego, and Eli Lilly and Co., of Indianapolis, said study results indicated that exenatide improved blood sugar levels as effectively as biphasic insulin aspart 30/70 (NovoMix 30, Novo Nordisk A/S) for people with Type II diabetes who fail to achieve acceptable blood sugar control on both metformin and a sulfonylurea

Neurocrine Biosciences Inc., of San Diego, completed the second off-treatment three-month period of its six-month proof-of-concept Phase II trial using its orally active small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist (NBI-56418) in endometriosis patients

Amylin Pharmaceuticals Inc., of San Diego, said 16-week study results of Symlin (pramlintide acetate) showed that adding the therapy to a regimen of basal insulin glargine in Type II diabetic patients who have not progressed to mealtime insulin therapy demonstrated a better overall glucose control, reduced glucose fluctuations, less use of insulin and weight loss, compared to those using basal insulin glargine alone...Nventa Biopharmaceuticals Corp., of San Diego, said a Phase II trial demonstrated

MediciNova Inc., of San Diego, completed enrollment in its Phase II/III trial of MN-001 in patients with interstitial cystitis (IC

Vical Inc., of San Diego, said a "prime-boost" vaccine regimen tested in 40 HIV-uninfected subjects in a National Institutes of Health-sponsored Phase I trial was safe and well tolerated, and was highly effective in inducing T-cell immune responses with multiple functions that may be important for controlling HIV infection

Vical Inc., of San Diego, started a National Institutes of Health-sponsored Phase I trial of a "prime-boost" vaccine approach designed to prevent or control disease in patients already infected with HIV

Halozyme Therapeutics Inc. , of San Diego, dosed the first three patients in a clinical trial of Enhanze technology, the company's drug delivery platform based on recombinant human PH20 hyaluronidase

TorreyPines Therapeutics Inc., of San Diego, started a Phase I trial for NGX426, an oral therapy that is intended to treat migraine and chronic pain conditions such as neuropathic pain

Somaxon Pharmaceuticals Inc., of San Diego, said Phase II data showed that a 40-mg dose of oral nalmefene demonstrated numerically higher abstinence rates in a smoking-cessation trial at all time points relative to placebo

TorreyPines Therapeutics Inc., of San Diego, completed its second Phase I study of NGX267 in Alzheimer's disease